Pharma Companies Get On Board With Regeneron To Speed Biobank Sequencing
Executive Summary
AbbVie, Alnylam, AstraZeneca and Pfizer join forces with Regeneron to speed up the sequencing of the 500,000 genetic samples in the UK's Biobank.
You may also be interested in...
Genomics Data Should Get More Attention In FDA Drug Review And Labeling, Regeneron Says
Regeneron advocates industry-FDA collaboration to establish regulatory standards for novel applications of genomic data, such as determining whether long-term outcomes studies are needed, and inclusion of the data in product labeling.
AstraZeneca Teams Up With Venter, Sanger To Mine Genomic Riches
AstraZeneca has entered into a series of early research collaborations in a bid to integrate genomics into the foundations of its entire drug discovery and development infrastructure.
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.